Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.52 |
| ▸ | BRCA1 | P38398 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.52 |
| ▸ | CASP1 | P29466 | 1/20 | 0.52 |
| ▸ | STAT6 | P42226 | 1/20 | 0.52 |
| ▸ | CASP7 | P55210 | 1/20 | 0.52 |
| ▸ | HBB | P68871 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | ESR1 | P03372 | 5/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | USP2 | O75604 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluorescin SCHEMBL31164674 | 0.98 | CYP2C9 (0.71) | CYP2C9ALDH1A1HSD17B10BRCA1CYP3A4 | |
| Fluorescin SCHEMBL31164673 | 0.98 | CYP2C9 (0.71) | CYP2C9ALDH1A1HSD17B10BRCA1CYP3A4 | |
| Fluorescin SCHEMBL29370997 | 0.98 | CYP2C9 (0.71) | CYP2C9ALDH1A1HSD17B10BRCA1CYP3A4 | |
| Fluorescin SCHEMBL31214151 | 0.98 | CYP2C9 (0.71) | CYP2C9ALDH1A1HSD17B10BRCA1CYP3A4 | |
| Fluorescin SCHEMBL27403 | 0.98 | CYP2C9 (0.71) | CYP2C9ALDH1A1HSD17B10BRCA1CYP3A4 | |
| Fluorescin SCHEMBL1938032 | 0.97 | CYP2C9 (0.69) | CYP2C9ALDH1A1HSD17B10BRCA1CYP3A4 | |
| Fluorescin SCHEMBL5579981 | 0.93 | CYP2C9 (0.64) | CYP2C9ALDH1A1HSD17B10BRCA1CYP3A4 | |
| Fluorescin SCHEMBL7807189 | 0.93 | CYP2C9 (0.64) | CYP2C9ALDH1A1HSD17B10BRCA1CYP3A4 | |
| Fluorescin SCHEMBL4342272 | 0.93 | CYP2C9 (0.64) | CYP2C9ALDH1A1HSD17B10BRCA1CYP3A4 | |
| Fluorescin SCHEMBL6036317 | 0.92 | CYP2C9 (0.62) | CYP2C9ALDH1A1HSD17B10BRCA1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2305246-B1 | Tumor necrosis factor inhibitors | UNIV PENNSYLVANIA (US) | 2015-08-26 | — | — | EP | disclosed |
| US-9096607-B2 | Tumor necrosis factor inhibitors | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140256803-A1 | TUMOR NECROSIS FACTOR INHIBITORS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2014-09-11 | — | — | US | disclosed |
| US-8765810-B2 | Tumor necrosis factor inhibitors | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2014-07-01 | — | — | US | disclosed |
| EP-2298295-B1 | Tumor necrosis factor inhibitors | CEPHALON INC (US) | 2013-08-28 | — | — | EP | disclosed |
| US-20130072562-A1 | TUMOR NECROSIS FACTOR INHIBITORS | CEPHALON, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-8318699-B2 | Tumor necrosis factor inhibitors | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2012-11-27 | — | — | US | disclosed |
| EP-2305246-A1 | Tumor necrosis factor inhibitors | Ception Therapeutics, Inc. (US) | 2011-04-06 | — | — | EP | disclosed |
| EP-2298295-A1 | Tumor necrosis factor inhibitors | Ception Therapeutics, Inc. (US) | 2011-03-23 | — | — | EP | disclosed |
| US-20090221527-A1 | TUMOR NECROSIS FACTOR INHIBITORS | CEPTION THERAPEUTICS, INC. (US) | 2009-09-03 | — | — | US | disclosed |
| EP-1845970-A4 | TUMOR NECROSIS FACTOR INHIBITORS | CEPTION THERAPEUTICS INC (US) | 2009-02-18 | — | — | EP | disclosed |
| EP-1845970-A2 | TUMOR NECROSIS FACTOR INHIBITORS | Ception Therapeutics, Inc. (US) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006083970-A2 | TUMOR NECROSIS FACTOR INHIBITORS | CEPTION THERAPEUTICS, INC. (US) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221527-A1 | TUMOR NECROSIS FACTOR INHIBITORS | TNFRSF1A, TNF, TNFRSF9 | CYP2C9 4775/4885ALDH1A1 3912/4885HSD17B10 3180/4885 |
| US-20140256803-A1 | TUMOR NECROSIS FACTOR INHIBITORS | TNFRSF1A, TNF, TNFRSF9 | CYP2C9 4775/4885ALDH1A1 3912/4885HSD17B10 3180/4885 |
| US-20130072562-A1 | TUMOR NECROSIS FACTOR INHIBITORS | TNFRSF1A, TNF, TNFRSF9 | CYP2C9 4775/4885ALDH1A1 3912/4885HSD17B10 3180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.